Barry Springer, PhD has 30 years' experience in drug discovery and platform development in both pharma and biotechnology companies with a focus on advanced therapies and innovative technologies. His broad experience includes many novel targets such as G-protein coupled receptors and spans small molecules to biologics and gene and cell therapies.
Former VP and Head, Janssen R&D
Former VP of Enabling Technologies, Johnson & Johnson